Medicare Spending on Ozempic and Other GLP-1s Is Skyrocketing | KFF
This policy watch analyzes the latest data on Medicare Part D spending on GLP-1 drugs, initially approved to treat diabetes but in high demand as treatments for obesity, and shows how spending on these drugs has increased substantially in recent years.| KFF
